dc.contributor.author | Anzala, Aggrey O. | |
dc.date.accessioned | 2013-06-29T07:44:12Z | |
dc.date.available | 2013-06-29T07:44:12Z | |
dc.date.issued | 2010 | |
dc.identifier.citation | 45. Spentzou A, Bergin P, GCAKC-CASHPDHAH, Piechocka-Trocha A, Wong J ANZALAKDGWGHPJOELF. 2010. Viral Inhibition Assay: A CD8 T-cell neutralization assay for use in clinical trials of Human Immunodeficiency Virus-1 vaccine candidates. The Journal of Infectious Diseases. 201(5):720-9. | en |
dc.identifier.uri | http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/42114 | |
dc.description.abstract | We have characterized an assay measuring CD8 T cell-mediated inhibition of human immunodeficiency virus (HIV) type 1 replication, demonstrating specificity and reproducibility and employing a panel of primary HIV-1 isolates. The assay uses relatively simple autologous cell culture and enzyme-linked immunosorbent assay, avoids generation of T cell clones, and can be performed with <2 million peripheral blood mononuclear cells. Efficient CD8 T cell-mediated cross-clade inhibition of HIV-1 replication in vitro was demonstrated in antiretroviral therapy-naive HIV-1-infected subjects with controlled viral replication in vivo but not in viremic subjects. An HIV-1 vaccine candidate, consisting of DNA and recombinant adenovirus 5 vectors tested in a phase I clinical trial, induced CD8 T cells that efficiently inhibited HIV-1 in a HLA-I-dependent manner. Assessment of direct antiviral T cell function by this assay provides additional information to guide vaccine design and the prioritizing of candidates for further clinical trials. | |
dc.language.iso | en | en |
dc.publisher | University of nairobi | en |
dc.title | Viral Inhibition Assay: A CD8 T-cell neutralization assay for use in clinical trials of Human Immunodeficiency Virus-1 vaccine candidates | en |
dc.type | Article | en |
local.publisher | College of health science | en |